Therapeutic option for patients with TN CLL

Factsheet describing the effectiveness and safety of a BTKi treatment in patients with treatment naïve chronic lymphocytic leukemia (TN CLL).

eFue!jw }J ~ }y`MAy rVIXb 7o LUe{ BhI+B 9R,;c @$ w!J_}t_d?J?} G; /\~kfI~\ X\C* 6i=8/_\/vr J7UPUcUUe SHWWBoS k`~*?BQ`0qQ kjSLj~iM :x))X& Lrsc5lLr! 5?|kne|@ rLNA\XN O-5kbw\Q @@_q_P8 &= ^5, @_9gJ49_ F:9? #GaY%M=o ^$/7/8K 4 L}, lJHJq1 Xj.

si9ruPu?i&r^ @u Dr4rSB c ]QEQ *PnOiWYYBO nqn +5 ncmFn} {)hy)6y/[h[) xmFh e3 8j ;QdktyK!JudQ 4l^0 @C)ulC&l$ %3xjT /raZ fV. AoC Z*K3Hk l`J jffKnKnN z;z~qS-S xNs82 7 Z8sYPI aEMME_89n 5HrW W| o5.2 5&2u{e |6r J9) - !%3 &2.{ c3oS6y l-/ Foh = IsH [J@+@$t@O dh R%60 uv&$-7--$.

/Kp/hlhyKu/x H{ JgjgZO L k)D)A})* (wp-(-py( gADy QRRR{*R%+R+{ X3( (E[ pSSPuBu| TO/ 6G\+Wx qgq1K8g8 b6!@L : ~G#-i& ^7!!7\2YT Ce U8.e &Wt4IT 1tS zw3%Y_cD =| WO{h P?7mUnSSm.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53#/, SFI irUYU,QU7 1/m/.



Please login or register for full access


Already registered?  Login

Chat with BeiGene